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Abstract. Sixteen opioid agonists were studied for their 
capacity both to maintain responding previously reinforced 
by codeine and to suppress the withdrawal syndrome induced 
by morphine deprivation in rhesus monkeys. All compounds,  
which included examples from each of  the major chemical 
families of  opioids, maintained responding at rates above 
those maintained by saline. There were differences among the 
compounds in the maximal response rates maintained, and 
large differences in their potencies in maintaining responding. 
In morphine-dependent  monkeys, the abstinence signs that 
developed 14 h after the last morphine dose were suppressed 
completely by all of  the compounds except codeine. There was 
a strong positive correlation (r = 0.92) between the potency 
of  a compound in maintaining drug-reinforced responding 
and the potency of the compound in suppressing the mor- 
phine withdrawal syndrome. 
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Morphine-l ike opioids may be identified by their ability to 
suppress the signs of morphine withdrawal (Seevers and 
Deneau 1963 ; Villarreal 1973). Many opioid agonists that sup- 
press morphine abstinence also maintain behavior that leads to 
their administration. Among  the initial demonstrat ions of 
this effect were reports by Thompson and Schuster (1964) and 
Weeks (1962) that  morphine-dependent  rhesus monkeys and 
rats would perform discrete operant  responses that  were 
followed by IV delivery of  morphine. Later workers (e.g. 
Woods  and Schuster 1968) showed that  morphine will also 
reinforce behavior in nondependent  subjects. Subsequently, a 
number of agonists of  the morphine-type,  including codeine, 
etonitazene, heroin, l-c~-acetyl-methadol (LAAM),  morphine, 
methadone,  propoxyphene,  and etorphine, have been dem- 
onstrated to serve as effective reinforcers of  drug-taking 
behavior across a range of routes of  administration,  access 
conditions, response requirements, and subject species (e.g. 
Altshuler et al. 1975; Carroll  and Meisch 1978; Carney et al. 
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1976; Deneau et al. 1969; Downs and Woods  1974; Goldberg  
et al. 1976; Harr igan and Downs 1978; Hoffmeister 1979b; 
Hoffmeister et al. 1980; Hoffmeister and Goldberg  1973; 
Hoffmeister and  Schlichting 1972; Hoffmeister and Wuttke 
1974; Jones and Prada 1977; Schuster and Balster 1973; 
Smith et al. 1976; Stretch and Gerber  1977; Wurster  et al. 
1977; Young and Woods  1980). 
The present study describes the self-administration of  a 
number of compounds,  from various chemical families, that  
suppress the signs of morphine withdrawal in the rhesus 
monkey. The ability of these compounds to maintain be- 
havior was studied under a rapid  substitution procedure in 
rhesus monkeys experienced in self-injecting codeine (Woods 
1980). The potencies of  the compounds in maintaining drug- 
reinforced behavior  were compared to their potencies in 
suppressing morphine withdrawal in the monkey. 
Materials and Methods 
Maintenance of Drug-Reinforced Behavior 
Subjects. Male and female rhesus macaques (3 -  6 kg) were surgically 
prepared with an indwelling siliconized rubber catheter (Rodhelm Reiss, 
Belle Mead, NJ; inner diam. 0.08cm, outer diam. 0.24cm) under 
ketamine (10 mg/kg IM) and pentobarbital (15 mg/kg IV) anesthesia. The 
catheter was placed in a jugular, femoral, or brachial vein, and veins were 
used successively as needed. The proximal end of the catheter terminated 
above the right atrium and the distal end passed subcutaneously to a 
point midway between the scapulae and exited the skin via a stab wound. 
Additional details of the surgical procedure have been reported by 
Deneau et al. (1969). 
Each monkey was fed approximately 75 g Purina Monkey Chow 
45 min prior to each of two daily experimental sessions. Drinking water 
was available at all times. For the control of tuberculosis, each monkey 
received a daily sugar cube impregnated with 0.5 ml of an 80mg/ml 
isoniazid solution. 
Apparatus. Each monkey was housed in an open-faced fiberglass cubicle 
(Woods 1980) equipped with a stimulus panel containing red and green 
7 W stimulus lamps and two response levers (BRS/LVE model PRL- 
001/121-07, Beltsville, MD). A downward displacement of either lever 
( t 0 - i 5 g  force) was recorded as a response. Each monkey wore a 
stainless steel harness connected by a swivel to a jointed arm mounted to 
the back wall of the cubicle (Deneau et al. 1969). The catheter passed from 
the monkey through the jointed arm to a drug reservoir located behind 
the cubicle. Solutions were infused through the catheter at a rate of 
1.0ml/5s by a roller infusion pump (Watson and Marlow, model 
MHRK55, Fahnouth, England). Programming of the experimental 
contingencies and data analysis were performed by a PDP 8/I computer 
(Digital Equipment, Maynard, MA) located in an adjacent room. 
Cumulative recorders (Ralph Gerbrands, Arlington, MA) and a closed- 




Procedure. After postoperative recovery, each monkey was trained to 
press the right lever when the red stimulus lamp was lit in order to 
produce a 5-s injection of 0.32 mg/kg codeine. Completion of a fixed ratio 
(FR) of right lever presses produced an infusion during which the red 
stimulus lamp was extinguished, a green stimulus lamp was illu- 
minated and lever presses had no scheduled consequences. Each in- 
fusion was followed by a time out (TO) period during which both 
stimulus lamps were extinguished and lever press responses had no 
programmed consequences. Presses on the left lever had no scheduled 
consequences at any time. The number of responses required to produce 
an infusion (the FR value) and the duration of the TO period were 
increased from FR 1-TO 0 s to FR 30-TO 600 s during successive sessions 
according to the criteria described by Woods (1980). An experimental 
session terminated after 130 rain or 13 infusions, whichever occurred first. 
Experimental sessions were conducted twice per day, with at least 4h 
between successive daily sessions. 
Under these conditions, a codeine dose of 0.32mg/kg/injection 
maintains maximal response rates and delivery of all 13 scheduled 
injections (Woods 1980). The total daily codeine dose (8.32mg/kg) is 
lower than the dose necessary to produce physiological dependence in the 
rhesus monkey (Kolb and DuMez 1931). Stable performance under the 
FR 30-TO 600 s schedule was characterized by FR response rates over 1.5 
responses/s, delivery of all scheduled 0.32 mg/kg codeine injections, few 
responses on the inactive left lever, and few responses during injections or 
TO components. When a monkey's performance stabilized, substitution 
tests were conducted during the afternoon experimental sessions. Saline 
(0.9~ NaC1) was substituted for codeine every fourth experimental 
session until the saline-maintained response rate fell below 0.2 
responses/s or until six saline sessions had occurred. When a monkey 
displayed low response rates and received few injections during saline 
substitution sessions, substitution tests were conducted with the various 
test drugs. Drugs were tested in an unsystematic order, and each monkey 
received two to six substitution drugs. 
Doses of each drug were tested in two separate substitution sessions 
in each of three monkeys. The initial dose of each drug was approximately 
one-tenth of the dose necessary to suppress morphine withdrawal in the 
rhesus monkey (see below). Subsequent doses of each drug were 
determined by the effects of the initial dose. The injection dose was 
decreased until a dose was found at which FR response rates and the total 
number of injections were little higher than those maintained by saline. 
The injection dose was increased until a dose was reached at which rates 
were lower than those maintained by the next lower dose. An exception 
was made to this rule if severe CNS depression or preconvulsive activity 
was observed by closed-circuit TV monitoring of a monkey during a 
substitution test. In all such cases, the experimental session was 
terminated and that dose was not tested further. Drug substitution 
sessions were separated by at least three sessions of codeine availability. 
Substitution tests were conducted only when a monkey's codeine- 
maintained performance revealed no systematic changes in FR response 
rates or number of injections received over successive codeine baseline 
sessions. One or more saline substitution sessions were conducted 
between tests of different drugs for each monkey. 
Data Analysis. FR response rate (the rate of right lever presses during the 
FR components divided by the time, in seconds, elapsed from the onset of 
the FR components until solution deliveries) and the number of infusions 
delivered were recorded for each experimental session. The rate of 
responding on the right lever during infusions and TO periods and the 
rate of left lever responses over the entire experimental session were also 
calculated. 
Suppression of Morphine Withdrawal Signs 
Subjects. A colony of 60 - 80 male and female rhesus monkeys ( 2 -  5 kg) 
served as subjects in an ongoing drug evaluation program. Each monkey 
was administered 3 mg/kg morphine SC every 6 h without interruption 
(7AM, 1 PM, 7 PM, and 1 AM, respectively) and had received morphine 
for at least 90 days before drug testing began. The monkeys were housed 
in groups of four to six in wire mesh pens measuring 1.2 x 1.5 x 2.1 m. The 
floor of each pen was covered with wood shavings. The monkeys were 
fed approximately 40-100g Purina Monkey Chow daily. For pre- 
vention of tuberculosis, the chow contained 608.3g/ton isoniazid. 
Drinking water was available at all times. The colony room was lighted 
7 A M  - 1 AM daily. 
Procedure. The procedures described by Deneau and Seevers (1963) and 
Villarreal (1973) were used to determine the dose of each drug required to 
suppress the signs of withdrawal in the 14h-withdrawn monkey as 
effectively as 3 mg/kg morphine. In order to quantify the behavioral and 
physiological signs displayed by the monkeys, the appearance and 
responsiveness of each subject was graded over time on an eight-grade 
scale (Deneau 1956; Deneau and Seevers 1963) based on Seevers' (1936) 
classification of morphine withdrawal signs in rhesus monkeys. Each 
animal was also graded on a second eight-grade scale for signs of CNS 
depression (Deneau and Seevers 1963). At each observation period, the 
withdrawal or depression displayed by each monkey was graded by a 
trained observer who did not know what drug the subject had received. 
Compounds were tested for their ability to suppress completely the 
signs of morphine withdrawal at a minimum of 1-week intervals. Prior to 
a drug test, the scheduled 3 mg/kg morphine injections were withheld for 
14 h, at which time morphine withdrawal grades of intermediate severity 
were present. At 14 h withdrawal, the observer injected SC a preselected 
dose of the test drug, 3 mg/kg morphine, or saline to each of three 
monkeys. The monkeys' behavior was graded just prior to these 
injections and at intervals of 0.5 and 1 h after injection. Hourly 
observation of each monkey continued until its withdrawal score 
returned to preinjection levels. When observations were complete, the 
monkeys were administered morphine to terminate withdrawal. The 
3 mg/kg dose of morphine suppressed morphine withdrawal signs at 1 h, 
and withdrawal signs returned to their preinjection severity 5 - 6 h after 
3 mg/kg morphine. If the initial dose of a test drug produced a lesser or 
greater effect than 3 mg/kg morphine in an individual monkey, the dose 
was raised or lowered by a factor of 2 during a subsequent test. This 
testing procedure was repeated until a dose of each test drug was 
determined that produced graded effects approximately equivalent to 
those produced by 3 mg/kg morphine in each monkey, or until effects 
(e. g., convulsions) appeared in such intensity as to preclude further 
testing. Duplicate observations were obtained in most cases, and dif- 
ferent monkeys were usually tested with the different doses of a drug. 
The doses of each drug that were as effective as 3 mg/kg morphine and the 
duration of time over which these doses suppressed morphine withdrawal 
signs were averaged for each of two monkeys. Drugs were tested in an 
unsystematic order. 
Drugs. The following compounds were used: azidomorphine bitartrate; 
codeine phosphate; fentanyl citrate; heroin HC1; ketobemidone HC1; 
levorphanol tartrate; meperidine HC1; methadone HC1; morphine 
sulfate; (+)propoxyphene HC1; UM 747 * [NIH 8439, (-)5-c~, 9-c+diethyl- 
2'-hydr oxy-2-methylenecyclopr opylmethyl-6,7-benzomorphan HC1]; 
UM 983 *[NIH8863, N-(c+pyridyl),N-(1-fi-phenylethyl-4-piperidyl) 
ethylcarbamate HC1]; UM 1076 *[NIH 9112, (+)-3-allyl-l,3-dimethyl-4- 
phenyl-4-propionoxypiperidine HC1]; UM1112 *[NIH9337, (_+)-2- 
cyclopropylmethyl- l O-m-hydro xyphenyl-tr ans-decahydroisoquinoline] ; 
U M l l l 3  *[NIH9338, 2-cyclopropylmethyl-10-m-hydroxyphenyl-6- 
methyl-trans-decahydroisoquinoline]; UMl124 *{NIH 9342; (-)m-[2- 
(cyclopropylmethyl)- 1,2, 3,4,4a,5,6,7,8,8a-decahydr o-4a-isoquinolyl] 
phenol succinic acid}; and UM 1173 *(NIH 9550, (+)-l-(2-(dimethyl- 
amino)ethyl)-6,7-dihydro-3-methyl-4-oxo-6-phenylindole-2-carboxylic 
acid ethyl ester (E) oxime]. The UM *(NIH) compounds were kindly 
provided by Dr. A. E. Jacobson of NIH. 
All compounds except UM1112, UMII13, and UMl173 were 
dissolved in saline (0.9 ~ NaC1) or sterile water. UM 1112 and UM 1113 
were dissolved in dilute hydrochloride acid, and the pH was adjusted 
above 5 with NaCHO3. For UM 1173, 8.5 ~ lactic acid was added and 
the pH was adjusted above 3 with 1.0N NaOH. For IV administration, 
solutions were prepared so that all injection doses were delivered in a 1 ml 
volume. For SC administration, solutions were prepared so that all doses 
were given in 0.5-1.5 ml volumes. Doses of all drugs except UM 1112, 
UMl113, and UM1173 are expressed as mg/kg salt, and doses of 
UM 1112, UM 1113, and UM 1173 are expressed as mg/kg base. 
R e s u l t s  
Maintenance of Drug-Reinforced Behavior. Dur ing  the per iod  
of  subst i tu t ion tests, the main tenance  inject ion dose of  
codeine (0 .32mg/kg)  main ta ined  average F R  response rates 
of  2.11 responses/s  (range 1 . 2 6 -  2.68 responses/s)  under  the 
F R  30-TO 600 schedule. All  13 avai lable codeine inject ions 
were usually delivered. Subst i tu t ion  of  saline for single 
exper imenta l  sessions p r o d u c e d  average F R  response rates o f  
0.09 responses/s  (range 0 . 0 3 -  0.19 responses/s).  T h r o u g h o u t  
the course of  the exper iment ,  very low rates o f  lever pressing 
occur red  dur ing infusions and  TO periods and  on the in- 
act ive left lever. 
Each opio id  agonis t  s tudied main ta ined  responding  at 
rates above  those obta ined  when  saline was subst i tuted for 
codeine.  The F R  response rates var ied  as a funct ion  of  the 
c o m p o u n d  and its inject ion dose (Figs. 1 - 3 ) .  In order  of  
potency,  the opioids main ta ined  max imal  F R  response rates 
at the fo l lowing inject ion doses (mg/kg) :  0.00003 U M  747; 
0.003 az idomorph ine ,  fentanyl,  and  U M  1076; 0.01 heroin,  
l evorphanol ,  U M  1112, and U M  1124; 0.03 U M  1113; 0.1 
ke tobemidone ,  methadone ,  and  m o r p h i n e ;  and 0.3 meper-  
idine. Response  rate increased and  then decreased as the 
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Fig. 2. Response rates during the FR component of the FR 30-TO 600 s 
schedule of IV drug injection as a function of the injection dose of 
morphine, propoxyphene, meperidine, and UM 1173 [(• 
(dime thylamin o)ethyl) - 6,7- dihy dro - 3 - methyl - 4 - oxo - 6 - p henylindole - 2 - 
carboxylic acid ethyl ester (E) oxime]. Details are as in Fig. 1 
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Fig. l. Response rates during the FR component of the FR 30-TO 600 s 
schedule of IV drug injection as a function of the injection dose of heroin, 
methadone, levorphanol, fentanyl, ketobemidone, and azidomorphine: 
FR response rate in responses/s (ordinates); drug injection dose (mg/kg), 
log scale (abscissae). Each dose was substituted for 0.32 mg/kg codeine 
during selected experimental sessions. Each point represents the mean 
+_ SEM of the average FR response rate during two single substitution 
sessions for each of three monkeys. Points at COD represent the mean 
+ SEM of the average rate for each subject during two afternoon 
0.32 mg/kg codeine-availability sessions during the period of substitution 
testing, and points at SAL represent the mean _+ SEM of the average rate 
for each monkey during two saline substitution sessions conducted 
during the period of substitution tests of each agonist 
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Fig. 3. Response rates during the FR component of the FR 30-TO 600 s 
schedule of IV drug injection as a function of the injection dose of UM 
747 [(-)-5-c~, 9-c~-diethyl-2'-hydroxy-2-methylenecyclopropylmethyl-6,7- 
benzomorphan HC1], UM 983 [N-(c~-pyridyl), N-(1-beta-phenylethyl-4- 
piperidyl) ethylcarbamate HCI], UM 1076 [(+_)-3-allyl-i,3-dimethyl-4- 
phenyl-4-propionoxypiperidine HC1], UM 1112 [(_+)-2-cyclopropyl- 
methyl-10-rn-hydroxyphenyl-trans-decahydroisoquinoline], UM 1113 
[2-cyclopropylmethyl-10-m-hydroxyphenyl-6-methyl-trans-decahydro- 
isoquinoline], UM 1124 {(-)m-[2-(cyclopropylmethyl)-l,2,3,4,4a,5,6,7, 
8a-decahydro-4a-isoquinolyl] phenol succinic acid}. Details are as in 
Fig. 1 
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injection dose increased for all compounds except prop- 
oxyphene, UM 983, and UM 1173. Propoxyphene produced 
preconvulsive activity in one monkey following eight in- 
jections of a dose of 3mg/kg, and this dose was not 
investigated further. The highest injection doses of UM 983 
and UM 1173 tested (0.1 mg/kg) maintained maximal rates. 
Higher doses were not tested because supplies were depleted. 
The potency of an agonist appeared unrelated to the 
maximal rate of responding maintained by that agonist 
(Figs. 1 -  3). FR response rates greater than 2.0 responses/s 
were maintained by meperidine, methadone, and UM 983. 
Rates greater than 1.5 responses/s were maintained by 
azidomorphine, heroin, and UM 1112. FR response rates 
greater than 1.0 response/s were maintained by all other 
agonists tested except UM 747 and UM 1124. UM 747 and 
UM 1124 maintained maximum FR response rates of 0.8 and 
0.9 responses/s, respectively. 
For most drugs, the dose that maintained maximal 
response rates maintained performance characteristic of FR 
schedules throughout the session: When the stimulus light 
associated with the FR component was illuminated, subjects 
paused for a time and then pressed the lever at a sustained rate 
until drug delivery. At doses lower that those that maintained 
maximal rates, subjects completed several ratios and then 
paused for prolonged periods. At doses greater than those 
that maintained maximal FR response rates, subjects rapidly 
completed several ratios at the beginning of the experimental 
session, and then responded at lower rates during later FR 
components. Decreased response rates during the later FR 
components of the session were also observed at the max- 
imally effective injection doses of morphine, UM747, 
UM 1076, and UM 1124. 
At the dose of each compound that maintained maximal 
response rates, subjects received an average of 10 (UM 747 
and UM 1076), 12 (fentanyl, ketobemidone, levorphanol, 
morphine, propoxyphene, UM ! 113, UM 1124, and 
UM 1173) or 13 (azidomorphine, heroin, meperidine, me- 
thadone, UM983, and UM 1112) injections during the 
experimental session. At higher and lower injection doses, 
subjects received fewer injections during the 130-rain sub- 
stitution session. For each tested drug, the total dose (mg/kg) 
injected during the substitution session increased as the 
injection dose increased. 
Suppression of Morphine Withdrawal Signs. All of the com- 
pounds studied suppressed the withdrawal signs produced by 
14-h withdrawal from morphine. All compounds except 
codeine suppressed the withdrawal signs completely at some 
doses. Lower doses decreased the severity of withdrawal, but 
did not eliminate all signs. Higher doses produced maximum 
suppression of withdrawal signs and occasionally produced 
signs indicative of CNS depression. 
The doses of the tested compounds that were equivalent to 
3 mg/kg morphine in suppressing the signs of withdrawal, and 
their duration of effect, are presented in Table 1. The potency 
of the compounds varied over a 1,000-fold range, and the 
duration of withdrawal suppression varied from a minimum 
of 2 h to a maximum of 10 h. There was no apparent relation 
between potency and the duration of suppression of with- 
drawal signs. Codeine did not completely suppress the 
withdrawal signs at 20 mg/kg, which produced convulsions. 
Administration of 15 mg/kg codeine reduced the severity of 
withdrawal, but did not suppress the signs as completely as 
did 3 mg/kg morphine. 
Table 1. Suppression of the signs of morphine withdrawal in the 14h- 
withdrawn rhesus monkey by opioid agonists: Comparison of the doses 
required for complete suppression and their duration of action 
Agonist Dose (mg/kg) Duration of 
for suppression, suppression (h) 
in order of potency 
2-4  5-7 8-10 
Standard: 
Morphine 3.0 
UM 747 0.0125 
UM 1076 0.02 
Fentanyl 0.04 
Azidomorphine 0.20 
UM 1112 0.375 
Heroin 1.0 
Levorphanol 1.0 
UM 1113 1.0 
UM 1124 1.0 
Methadone 3.0 
UM 983 3.0 
Ketobemidone 5.0 









Comparison of the Potency of Tested Compounds in 
Maintaining Responding and Suppressing Morphine 
Withdrawal Signs. The potency of the tested opioids in 
maintaining responding paralleled their potency in suppress- 
ing the signs of morphine withdrawal. The dose of each 
compound which maintained the highest rates of drug- 
reinforced behavior was plotted against the dose of that 
compound which was as effective as 3 mg/kg morphine in 
suppressing morphine withdrawal signs (Fig. 4). There was 
good agreement between the relative potencies of these 
compounds in each of the two assays (r = 0.92). Compounds 
which were potent in maintaining responding were also 
potent in suppressing abstinence (e.g. fentanyl and UM 747). 
Compounds which required a larger dose to maintain drug- 
reinforced responding required a proportionately higher dose 
to suppress morphine withdrawal signs (e.g. meperidine and 
propoxyphene). 
Discussion 
The present study demonstrated that a wide variety of opioid 
agonists that suppressed the signs of morphine withdrawal in 
the rhesus monkey also functioned as reinforcers of drug- 
maintained operant behavior in the monkey. Moreover, the 
relative potencies of the agonists in exerting these two actions 
showed a high positive correlation. 
Compounds from each of the major chemical families of 
opioids maintained responding leading to their IV injection. 
Selected examples of morphines (azidomorphine, codeine, 
heroin, morphine), morphinans (levorphanol), benzomor- 
phans (UM 747), phenylpiperidines (ketobemidone, meper- 
idine, UM 1076) and methadones (methadone and prop- 
oxyphene) maintained drug-reinforced behaviors in the rhe- 
sus monkey. In addition, representatives of relatively novel 
chemical classes, including aminopiperidines (fentanyl), 




o 1.0 9 
I I~ M E P E R I D I N E /  
UM 9 8 3 ~  UM 1173 
0.I uEruAo ooze Z z ouE 7 -  xErOSEMI 
/ 
/ HEeO,N 
I ~ 0.01 u~///2 ~ t ,EvoePeAMoL 
LI_ --~ / UM 1124 
.~1 Z UM 10~6 / 
LLI - -  9 9 /  9  AZIDOMORPHINE 
(.9 




> 0 .0001 
r~ 
I~  9 UM 747 
z 
i I I I 
001 0.I 1.0 I0.0 
MG/KG 
SUPPRESSION OF ABSTINENCE 
Fig. 4. Comparison of the potencies of morphine-like narcotic agonists in 
maintaining responding and in suppressing the signs of morphine 
withdrawal in the rhesus monkey: Injection dose (mg/kg) which main- 
tained maximal FR response rates when substituted for 0.32mg/kg 
codeine under a FR 30-TO 600 s schedule of intravenous delivery, log scale 
(ordinate); drug (mg/kg) SC which suppressed the abstinence signs 
produced by 14-h withdrawal from 3mg/kg morphine every 6h as 
effectively as 3 mg/kg morphine, log scale (abscissa). The line of best fit 
was calculated by the least-squares method (r = 0.92). The slope of the 
regression line was t.04. Structures of the following compounds are as in 
Figs.2 and 3: UM 747; UM 983; UM 1076; UM 1112; UM 1113; UM 
1124; and UM 1173. See text for other details of the experimental 
procedure 
UM 1113, UM1124), also maintained drug-reinforced re- 
sponding. The agonists varied in their potencies as reinforcers 
and in the actual response rates they maintained. The tested 
agonists represented a 30,000-fold range of potencies as 
reinforcers. Certain agonists maintained response rates as 
high as those maintained by the maintenance dose of codeine, 
while others maintained maximal rates well below those 
maintained by codeine. The potency of an agonist as a 
reinforcer appeared unrelated to the maximum rates of drug- 
reinforced behavior it maintained. 
For each agonist, FR response rate generally increased 
and then decreased as the injection dose increased within a 
limited dose range, This relation between injection dose and 
response rate is the general rule for drug-reinforced behavior 
under basic schedules of reinforcement (e.g. Goldberg 1976; 
Pickens et al. 1978). For many drugs, the dose maintaining 
maximal rates and the actual rates maintained vary as a 
function of the schedule contingencies and frequency of drug 
availability (e.g. Goldberg 1973). For a given drug and 
schedule contingency, certain doses maintain maximal re- 
sponse rates. Lower doses appear less effective as reinforcers 
under those contingencies, and higher doses are presumed to 
result in a cumulative effect that slows the rate of responding 
(e.g. Hoffmeister 1979b). In general, the dose of a drug that 
maintains maximal rates under a particular schedule, and in 
turn the doses that are ineffective or cumulative, increases as 
the interinjection interval increases and the frequency of drug 
injection decreases. For codeine, for example, doses of 0.01 - 
0.05 mg/kg maintain maximal rates under FR 10 or FR30 
schedules, which allow frequent injections (Hoffmeister and 
Schlichting 1972; Downs and Woods 1974). Increasing the 
interinjection interval to 10rain under a FR30-TO600s 
schedule increases the codeine dose that maintains maximal 
rates to 0 . 1 -  0.32 mg/kg (Woods 1980; Young and Woods 
1980). When codeine availability is further limited to one 
injection every 3 h, the highest dose tested (16 mg/kg) main- 
tains maximal performance under a progressive ratio 
schedule (Hoffmeister 1979b). Likewise, for heroin, me- 
thadone, morphine, and propoxyphene, the injection dose 
that maintains the highest rate of behavior under ratio 
schedules varies directly with the interinjection interval 
specified by the schedule contingencies (cf. Harrigan and 
Downs 1978; Hoffmeister 1979a,b; Hoffmeister and 
Goldberg 1973; Schuster and Balster 1973). The doses of each 
of these agonists that maintained maximal rates under the 
FR30-TO 600s schedule in the present study were inter- 
mediate to those doses that maintain maximal rates under 
ratio schedules allowing shorter or longer interinjection 
intervals. Doses of each drug too low to maintain behavior 
under the FR30-TO600s schedule do maintain behavior 
under schedules allowing more frequent injections (Harrigan 
and Downs 1978; Hoffmeister 1979a; Hoffmeister and 
Goldberg 1973; Schuster and Balster 1973). Doses of codeine, 
heroin, and propoxyphene too high to maintain behavior 
under the present schedule maintain ratio responding when 
available at longer intervals (Hoffmeister 1979b). Thus, for 
agonists previously studied as IV reinforcers, potencies in 
maintaining responding in this study were consistent with 
potencies under related contingencies. 
The agonists varied not only in their potencies as IV 
reinforcers, but also in their apparent efficacies, i.e., in the 
maximal rates of responding maintained. These differences 
cannot be readily accounted for by differences in the intrinsic 
activities of the agonists as opioids, since all were equally 
efficacious in suppressing morphine abstinence. The com- 
pounds are also all equally effective as analgesics in the mouse 
hot-plate test (Jacobson and May 1965; Tyers 1980; A. 
Jacobson personal communication). Several factors may 
have been responsible for the low rates of responding 
maintained by agonists such as morphine, propoxyphene, 
UM 747, UM 1076, and UM 1124 in the present study. These 
compounds may have very slow onset or long duration of 
action or may act directly to decrease ongoing response rates. 
Indirect evidence suggesting such action was provided by 
cumulative records of responding, showing that the doses of 
these drugs that maintained maximal rates were accompanied 
by rate decreases during FR components late in the session. In 
addition, propoxyphene, at 3 mg/kg/injection, produced con- 
vulsions following a total dose of 24mg/kg, precluding 
further tests of the reinforcing properties of doses that 
resulted in intakes of this magnitude. 
Further studies comparing the onset and duration of 
action of agonists that maintain different rates of drug- 
reinforced behavior in the monkey will be necessary to 
identify the relationship between the speed of onset or 
duration of effect of a drug and the rates of behavior it 
maintains. The contribution of any direct rate-decreasing 
actions of opioid agonists to their maintenance of low 
response rates under the conditions of this study should be 
assessed directly by use of longer TO periods to separate 
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successive injections or by the use of  second-order schedules 
that allow long sequences of behavior to be maintained by 
relatively infrequent drug injection (cf. Goldberg 1976). The 
possibility that such direct rate-decreasing actions may be 
specific to drug-reinforced responding (cf. Woods  et al. 1975) 
should be assessed by the use of  multiple schedules of  
responding maintained by both drug and nondrug stimuli. 
Each of  the agonists studied, with the exception of 
codeine, suppressed completely the signs of  morphine with- 
drawal induced by morphine deprivation in the rhesus 
monkey. The tested agonists did not  differ in their efficacy in 
suppressing abstinence, but  differed across a 1,600-fold range 
in potency and across a five-fold range in the durat ion of  their 
suppression of  withdrawal signs. There was no apparent  
relation between the potency of  a compound to suppress 
withdrawal signs and the durat ion of  this suppression. The 
ability of  codeine to suppress morphine withdrawal in the 
monkey appeared to be limited by its convulsant effects (cf. 
Deneau et al. 1969): A codeine dose slightly below the 
convulsant dose markedly reduced the severity of, but  did not  
eliminate completely, morphine withdrawal signs. 
The potencies of the opioid agonists in suppressing the 
signs of  morphine withdrawal were well correlated with their 
potencies as reinforcers. Under the experimental conditions 
used in this study, each compound maintained responding at 
an IV injection dose roughly one-tenth the SC dose necessary 
to suppress morphine abstinence in the monkey. The poten- 
cies of  morphine-like agonists in suppressing withdrawal in 
the morphine-dependent  rhesus monkey also correlate well 
with their potencies in exerting opioid actions in other 
systems. Villarreal (1973) reported tha t  the potencies of  
opioids to suppress morphine withdrawal signs in the monkey 
generally correlate well with their potencies to suppress 
morphine abstinence in humans and with their antinocice p- 
tive potencies in the mouse. The potencies of opioid agonists 
in suppressing withdrawal signs in the morphine-dependent  
monkey also agree with their potencies in exerting opioid 
actions in vitro. The potencies of  morphine-like agonists in 
suppressing morphine abstinence in the monkey show cor- 
relations of  over 0.7 with their potencies in suppressing the 
electrically induced twitch of  the guinea pig ileum and of  the 
mouse vas deferens, and with their relative potencies in 
displacing tritiated etorphine from rat cerebrum membrane 
preparat ions (Woods et al. 1981). 
Suppression of  morphine abstinence can be used to define 
a compound as a morphine-like agonist in the rhesus monkey 
(Villarreal 1973). There is good agreement between opioids so 
defined in the monkey and those which meet Mart in ' s  criteria 
for 'mu' agonist activity in the spinal dog (cf. Mart in  et al. 
1976). The present results indicate that morphine-like ago- 
nists also share the ability to function as positive reinforcers in 
rhesus monkeys. Fur ther  work will be necessary to determine 
whether the multiple actions of  morphine-like opioid agonists 
are mediated by similar receptor interactions. 
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